关注
Michael Nauck
Michael Nauck
Professor der Diabetologie, Ruhr-Universität Bochum
在 rub.de 的电子邮件经过验证
标题
引用次数
引用次数
年份
Liraglutide and cardiovascular outcomes in type 2 diabetes
SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ...
N Engl J Med 2016 (375), 311-322, 2016
71372016
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
Diabetes care 35 (6), 1364-1379, 2012
5181*2012
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
DJ Drucker, MA Nauck
The Lancet 368 (9548), 1696-1705, 2006
46952006
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
Diabetes care 38 (1), 140-149, 2015
36722015
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
Diabetologia 55, 1577-1596, 2012
3006*2012
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
DIABETOLOGIA 56 (3), 680-680, 2013
2156*2013
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
MA Nauck, MM Heimesaat, C Orskov, JJ Holst, R Ebert, W Creutzfeldt
The Journal of clinical investigation 91 (1), 301-307, 1993
19631993
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes
MA Nauck, F Stöckmann, R Ebert, W Creutzfeldt
Diabetologia 29 (1), 46-52, 1986
17761986
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in …
M Nauck, A Frid, K Hermansen, NS Shah, T Tankova, IH Mitha, ...
Diabetes care 32 (1), 84-90, 2009
15462009
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients
MA Nauck, N Kleine, C Ørskov, JJ Holst, B Willms, W Creutzfeldt
Diabetologia 36, 741-744, 1993
14111993
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
MA NAUCK, E HOMBERGER, EG SIEGEL, RC ALLEN, RP EATON, ...
The Journal of Clinical Endocrinology & Metabolism 63 (2), 492-498, 1986
11781986
Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio, DJ Drucker, PR Flatt, ...
Molecular metabolism 30, 72-130, 2019
11552019
Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
MA Nauck, U Niedereichholz, R Ettler, JJ Holst, C Ørskov, R Ritzel, ...
American Journal of Physiology-Endocrinology And Metabolism 273 (5), E981-E988, 1997
11511997
Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects
CF Deacon, MA Nauck, M Toft-Nielsen, L Pridal, B Willms, JJ Holst
Diabetes 44 (9), 1126-1131, 1995
11471995
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
S Lim, JH Bae, HS Kwon, MA Nauck
Nature Reviews Endocrinology 17 (1), 11-30, 2021
11452021
Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on …
MA Nauck, G Meininger, D Sheng, L Terranella, PP Stein
Diabetes, Obesity and Metabolism 9 (2), 194-205, 2007
9542007
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European …
SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, ...
Diabetologia 58, 429-442, 2015
9152015
GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier
Molecular metabolism 46, 101102, 2021
7702021
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
RE Pratley, M Nauck, T Bailey, E Montanya, R Cuddihy, S Filetti, ...
The Lancet 375 (9724), 1447-1456, 2010
7642010
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp …
MA Nauck, MM Heimesaat, K Behle, JJ Holst, MS Nauck, R Ritzel, ...
The Journal of Clinical Endocrinology & Metabolism 87 (3), 1239-1246, 2002
7482002
系统目前无法执行此操作,请稍后再试。
文章 1–20